Horizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
|
|
- Marian Hutchinson
- 5 years ago
- Views:
Transcription
1 Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. Tildrakizumab is intended for use in patients with moderate to severe plaque psoriasis who have failed to respond to, have contraindications to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (psoralen ultraviolet light) therapy. If licensed, it will offer an additional treatment option for these patients who have not responded to topical or systemic therapies, and offer an alternative to other biological agents. Tildrakizumab is a high affinity humanised IgG1/k monoclonal antibody. It specifically targets the interleukin-23 (IL-23) p19 subunit, a receptor which plays an important role in the pathogenesis of autoimmune inflammation, by stimulating the production of Th17 cells, which in turn produce proinflammatory molecules. Tildrakizumab does not currently have Marketing Authorisation in the EU for any indication. The prevalence of psoriasis in England is estimated to be around 1.63%, equating to approximately 900,000 people with the condition. Plaque psoriasis accounts for around 90% of cases and approximately 20% have moderate to severe psoriasis (15% moderate, 5% severe). The estimated prevalence of people currently eligible for biological therapy in England is 3% of those with psoriasis, equating to around 27,000 people. However, because of the nature of the condition, not all patients eligible for biologic treatments will currently be identified and treated with them. In , there were 1,454 hospital admissions in England as a result of psoriasis vulgaris equating to 1,537 finished consultant episodes and 3,912 bed days. Thirty deaths from psoriasis were registered in England and Wales during Treatment options for psoriasis aim to reduce symptoms and improve patient quality of life. Topical treatments are usually offered as first line therapy, followed by phototherapy and/or systemic therapies as second line treatment, and biological therapies as third line treatment regimes. Tildrakizumab is in three phase III clinical trials comparing its effect on Psoriasis Area Severity Index (PASI) against treatment with etanercept or placebo. These trials are expected to be completed by This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. NIHR Horizon Scanning Centre, University of Birmingham nihrhsc@contacts.bham.ac.uk Web:
2 TARGET GROUP Plaque psoriasis: moderate to severe patients who have failed to respond to, have a contraindication to, or are intolerant to other systemic therapies. TECHNOLOGY DESCRIPTION Tildrakizumab (SCH ; MK-3222; anti-il-23 MAb) is a high affinity humanised IgG1/k monoclonal antibody. It specifically targets the interleukin-23 (IL-23) p19 subunit, a receptor which plays an important role in the pathogenesis of autoimmune inflammation, by stimulating the production of Th17 cells, which in turn produce pro-inflammatory molecules. Tildrakizumab is intended for use in patients with moderate to severe plaque psoriasis who have failed to respond to, have contraindications to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (psoralen ultraviolet light) therapy. Tildrakizumab is administered subcutaneously (SC); in the phase III clinical trials, a dose of either 200mg or 100mg was administered at weeks 0, 4, 16 and Tildrakizumab does not currently have Marketing Authorisation in the EU for any indication. INNOVATION and/or ADVANTAGES If licensed, tildrakizumab will offer an additional treatment option for patients with plaque psoriasis who have not responded to topical or systemic therapies, and will offer an alternative to other biological agents. DEVELOPER Merck Sharp & Dohme Ltd. AVAILABILITY, LAUNCH OR MARKETING In phase III clinical trials. PATIENT GROUP BACKGROUND Psoriasis is an inflammatory skin condition characterised by well-defined, sharply demarcated, erythematous plaques, which can be one centimetre to several centimetres in size. Plaques may form across specific areas such as the scalp, trunk, limbs, buttocks, elbows and knees, but can also manifest across the entire body causing pain and pruritus. Plaques appear as dry, thin, silvery-white scales, and often smaller plaques merge forming larger plaques, particularly over the leg and trunk 2,3. The cause of psoriasis is not known although genetics, the environment, and an overactive immune system (in particular T cells) are thought to play a part 4. Psoriasis typically follows a relapsing and remitting course, with flare ups occurring spontaneously 5. Contributors to flare ups include stress, infections, medications, sunlight, trauma, hormonal changes, smoking and alcohol 3. 2
3 Patients with psoriasis often experience feelings of self-consciousness and embarrassment, and as a result, may suffer unemployment, social isolation, and depression; all factors which contribute to a reduction in overall patient quality of life 6. The adverse psychosocial issues associated with the condition also contribute to worsening outcomes for patients with psoriasis 7. NHS or GOVERNMENT PRIORITY AREA This topic is relevant to: Department of Health. Improving quality of life for people with long term conditions (2013). NHS England NHS Standard Contract for Specialised Dermatology Services (All ages). A12/S/a. CLINICAL NEED and BURDEN OF DISEASE The prevalence of psoriasis in England is estimated to be around 1.63%, equating to approximately 900,000 people with the condition 8,a. Plaque psoriasis accounts for around 90% of cases and approximately 20% have moderate to severe disease (15% moderate, 5% severe) 8. Onset may occur at any age, although it is uncommon in children (prevalence 0.71%), with the majority of cases occurring before the age of 35. Life expectancy in men and women with severe psoriasis is reduced by 3.5 and 4.4 years respectively 9, primarily due to metabolic syndrome and heart disease 10. Females typically develop plaque psoriasis earlier than males, and patients with a positive family history for psoriasis also tend to have an earlier age of onset 12. Acute flares or relapses of plaque psoriasis may evolve into more severe disease, such as pustular or erythrodermic psoriasis 5. The estimated prevalence of people currently eligible for biological therapy in England is 3% 11 of those with psoriasis, equating to around 27,000 people. However, because of the nature of the condition, not all patients eligible for biologic treatments will currently be identified and/or treated with these agents 11. In , there were 1,454 hospital admissions in England as a result of psoriasis vulgaris (ICD-10 L40.0), equating to 1,537 finished consultant episodes and 3,912 bed days 12. Thirty deaths from psoriasis were registered in England and Wales during 2013 (ICD-10 L40) 13. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance NICE technology appraisal in development. Psoriasis (plaque, moderate to severe) - apremilast [ID679]. Expected August NICE technology appraisal in development. Secukinumab for treating moderate to severe plaque psoriasis [ID718]. Expected July NICE technology appraisal. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180). September NICE technology appraisal. Adalimumab for the treatment of adults with psoriasis (TA146). June a Based on Office for National Statistics mid-2013 population estimate for England. 3
4 NICE technology appraisal. Infliximab for the treatment of adults with psoriasis (TA134). January NICE technology appraisal. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103). July NICE clinical guideline. Psoriasis: The assessment and management of psoriasis (CG153). October NICE quality standard. Psoriasis (QS40). August NICE interventional procedure guidance. Grenz rays therapy for inflammatory skin conditions (IPG236). November Other Guidance Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults (121) British Association of Dermatologists and Primary Care Dermatology Society. Clinical guideline: Recommendations for the initial management of psoriasis British Association of Dermatologists. Guidelines for biologic interventions for psoriasis CURRENT TREATMENT OPTIONS Treatment options for psoriasis aim to reduce symptoms and improve patient quality of life. Topical treatments are usually offered as first line therapy, followed by phototherapy and/or systemic therapies as second line treatment, and biological therapies as third line treatment regimes. The majority of psoriasis cases are managed at the primary care level, though up to 60% of patients may require referral to a specialist 5. Current treatment options for plaque psoriasis include 16,17,18,19 : Topical (alone or in combination) Emollients. Corticosteroids: betamethasone dipropionate. Vitamin D analogues: calcipotriol, calcitriol, tacalcitol (with or without phototherapy). Tars (with or without phototherapy). Dithranol (with or without phototherapy). Retinoids: tazarotene. Salicyclic acid. Tacrolimus ointment (not licensed for this indication). Phototherapy Broad- or narrow-band UVB and psoralen and UVA combination (PUVA). Systemic conventional disease modifying therapies (for the treatment of patients with moderate to severe or refractory psoriasis) Oral retinoids: acitretin (with or without phototherapy). Hydroxycarbamide (not licensed for this indication). Ciclosporin. Methotrexate. 4
5 Fumaric acid esters: Fumaderm (not licensed in the UK for this indication) b. Apremilast. Biological therapies (for the treatment of patients with moderate to severe psoriasis who are candidates for systemic therapies) Secukinumab (IL-17A inhibitor). Biological therapies (for the treatment of patients intolerant, contraindicated or refractory to other systemic conventional disease modifying treatments and/or phototherapy) Adalimumab (TNF- Etanercept (TNF-inhibitor). Infliximab (TNF- Ustekinumab (IL-12 and IL-23 inhibitor). EFFICACY and SAFETY Trial Sponsor NCT , MK , ; tildrakizumab vs etanercept vs placebo; phase III. Merck Sharp & Dohme Corp. NCT , MK , P07771; tildrakizumab vs etanercept vs placebo; phase III extension. Merck Sharp & Dohme Corp. NCT , MK , , P07770; tildrakizumab vs placebo; phase III extension. Merck Sharp & Dohme Corp. Status Ongoing. Ongoing. Ongoing. Source of Trial registry 1. Trial registry 20. Trial registry 21. information Location Not reported. Not reported. Not reported. Design Randomised, active- and placebo-controlled. Randomised, activecontrolled. Randomised, placebocontrolled. Participants n=1,050 (planned); aged 18 years and older; moderate to severe plaque psoriasis; candidate for phototherapy or systemic therapy. Inclusion criteria for extension studies: must have completed part 2 and achieved at least Psoriasis Area Severity Index (PASI) c 50 response by the end of part 2. n=1,050 (planned); aged 18 years and older; moderate to severe plaque psoriasis; candidate for phototherapy or systemic therapy; must have completed part 3 of previous NCT study and achieved at least PASI 50 response by the end of part 3. n=885 (planned); aged 18 years and older; moderate to severe plaque psoriasis; candidate for phototherapy or systemic therapy. Inclusion criteria for extension studies: must have completed part 3 and achieved at least a PASI 50 response by the end of part 3; received active tildrakizumab treatment within 12 weeks prior to the end of part 3. Schedule Part 1 (weeks 0-12), part 2 (weeks 12-18). Randomised to: Arm 1: tildrakizumab 200mg SC on weeks 0, 4, 16 and 28; in combination with etanercept placebo SC, twice weekly up to Part 1 (week 0-12), part 2 (week 12-28). Randomised to: Arm 1: tildrakizumab 200mg SC on weeks 0, 4, 16 and 28; in combination with etanercept placebo twice weekly up to week Randomised to: tikdrakizumab 200mg or 100mg SC; or placebo SC, all at week 0 and 4 for 12 b Expert personal communication. c PASI is an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of body surface area. 5
6 week 12, and then once weekly through to week 28. Arm 2: tildrakizumab 100mg SC on weeks 0, 4, 16, and 28; in combination with etanercept placebo SC, twice weekly up to week 12, then once weekly up to week 28. Arm 3: placebo SC on weeks 0 and 4 in combination with etanercept placebo SC, twice weekly up to week 12, then once weekly up to week 28. Participants are re-randomised at week 12 to receive tildrakizumab 100mg SC or 200mg SC on weeks 12, 16, and 28. Arm 4: tildrakizumab placebo SC on weeks 0 and 4; in combination with etanercept 50mg SC twice weekly up to week 12 and then once weekly through week 28. Eligible participants that choose to enrol in the extension study will have an additional treatment period of up to 192 weeks and will be followed for an additional 20 weeks in each follow-up period. Each participant will receive tildrakizumab 200mg or 100mg SC every 12 weeks for up to study week 220 according to their treatment assignment at the end of part 2. 12, and then once weekly through to week 28. Arm 2: tildrakizumab 100mg SC on weeks 0, 4, 16, and 28; in combination with etanercept placebo twice weekly up to week 12, then once weekly up to week 28. Arm 3: placebo SC on weeks 0 and 4 in combination with etanercept placebo twice weekly up to week 12, then once weekly up to week 28. Participants are re-randomised at week 12 to receive tildrakizumab 100mg SC or 200mg SC on weeks 12, 16, and 28. Arm 4: tildrakizumab placebo SC on weeks 0 and 4; in combination with etanercept 50mg SC twice weekly up to week 12 and then once weekly through week 28. Part 3 (week 28-52). Arm 1: participants with a PASI 75 response at week 28 will be re-randomised to either continue tildrakizumab 200mg or 100mg SC at weeks 28, 40 and 52; PASI 50 response but <PASI 75 response will continue to receive tildrakizumab every 12 weeks; no PASI 50 response will be discontinued from the study. Arm 2: participants with PASI 75 response at week 28 will continue to receive tildrakizumab 100mg every 12 weeks; PASI 50 response but <PASI 75 response will be rerandomised to receive tildrakizumab 100mg or 200mg SC every 12 <PASI 50 response will be discontinued from the study. Arm 3: participants will continue to receive treatment every 12 weeks 6
7 Follow-up Active treatment period 28 weeks, follow-up 20 Primary outcome/s Secondary outcome/s Expected reporting date PASI 75 at week 12, Physician s Global Assessment (PGA) d score. PASI 90 at week 12 and 28, Dermatology Life Quality Index (DLQI), DLQI score of 0 or 1 at week 12, Nail Psoriasis Severity Index (NAPSI) at week 12 and 28, safety. Study completion date reported as Aug according to their rerandomised treatment assignment. Arm 4: >PASI 75 response at week 28 will be discontinued from the study; <PASI 75 response at week 28 will be crossed over to tildrakizumab 200mg SC at week 32, 36 and 28. Active treatment period 52 weeks, follow-up 20 PASI 75 at week 12, PGA score, safety. PASI 75 at week 28, PGA score at week 28, PASI 90 at week 12 and 28, PASI 100 score at week 12 and 28, DLQI at week 12 and 28, DLQI of 0 or 1 at week 12 and 28, NAPSI at week 12. Study completion date reported as Oct Active treatment period 12 PASI 75 at week 12, PGA score, safety. PASI 90, PASI 100, DLQI, DLQI score of 0 or 1 at week 12. Study completion date reported as Aug Trial Sponsor Status Source of information Location Design Participants Schedule NCT , P05495, , MK ; tildrakizumab vs placebo; phase II. Merck Sharp & Dohme Corp. Complete and published in abstract. Abstract 22, trial registry 23. EU (inc UK), USA, Canada and other countries. Randomised, placebo-controlled. n=339; aged 18 years and older; moderate to severe chronic plaque psoriasis defined by disease affecting moderate or greater score on PGA; ; diagnosis of predominantly months; candidate for phototherapy or systemic therapy. Patients were randomised to 5 groups. In part 1 of the study, all patients in each group received the specified dose of treatment or placebo at week 0 and week 4. In part 2, patients within each group were divided into responders (R) and non-responders (NR) and received a specified SC dose of tildrakizumab at week 16 then once every 12 Part 1 Group 1, tildrakizumab 5mg SC; group 2, tildrakizumab 25mg SC; group 3, tildrakizumab 100mg SC; group 4, tildrakizumab 200mg SC; group 5, placebo SC. Part 2 Group 1, R: tildrakizumab 5mg SC, NR: tildrakizumab 100mg SC; group 2 R: tildrakizumab 25mg SC, NR: tildrakizumab 100mg SC; group 3, R: tildrakizumab 100mg or 25mg SC, NR: tildrakizumab 200mg SC; group 4, R: tildrakizumab 200mg or 100mg SC, NR: tildrakizumab 200mg SC; group 5, R: tildrakizumab 25mg SC, NR: tildrakizumab 100mg SC. d The PGA measures the physician s impression of the disease (psoriasis). 7
8 Follow-up Active treatment period 52 weeks, follow-up until week 72. Primary 75 at week 16. outcome/s Secondary 75 at week 12; PGA of cleared or minimal at week 16. outcome/s Key results No significant difference was observed in PASI 75 at week 52 following dose reduction from 200mg to 100mg vs. remaining on 200mg at week 16. There was a significant loss of PASI 75 (p=0.005) and PGA (p=0.02) response at week 52 following dose reduction from 100mg to 25mg vs. remaining on 100mg. PASI 75 and PGA responders at week 52 generally maintained response following study drug discontinuation; PASI 75 responses for the 100mg to 100mg group (part 1 to part 2 dose) was 97% and 96% at weeks 52 and 72, respectively, 70% and 62% for 100mg to 25mg group, 97% and 89% for 200mg to 200mg group and 91% and 70% for 200mg to 100mg group. Median time to relapse (i.e., >50% reduction of week 52 improvement from baseline) in subjects receiving 100mg was 21.5 Less than 50% of subjects receiving 200mg had >50% reduction in PASI score by week 72. Adverse Serious AEs that were possibly related to tildrakizumab included bacterial arthritis and effects (AEs) lymphoedema, melanoma, stroke, epiglottis and knee infection. ESTIMATED COST and IMPACT COST The cost of tildrakizumab is not yet known. The costs of other selected biological therapies for psoriasis are detailed below 24e. Drug Dose Unit cost Annual cost Adalimumab Initially 80mg SC, then 40mg on (40mg, 9,295. (Humira) alternate weeks, one week after initial dose. prefilled syringe). Etanercept 25mg SC twice weekly or 50mg once (25mg, 9,295. (Enbrel) Infliximab (Remicade) Ustekinumab (Stelara) weekly. 5mg/kg intravenously repeated 2 weeks and 6 weeks after initial dose and then every 8 Initially 45mg SC, then 45mg 4 weeks after initial dose, then 45mg every 12 prefilled syringe) (100mg, vial). 2,147 (45mg, prefilled syringe). 10,910 f. 12,882. IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Other: Impact on quality of life of families/carers and patients, including social wellbeing and education Reduced symptoms or disability No impact identified e Based on an average weight of 77.3kg. Assumes wastage. f Following loading doses and based on an average 6.5 doses per year 8
9 Impact on Health and Social Care Services Increased use of existing services Re-organisation of existing services Other: Decreased use of existing services Need for new services None identified Impact on Costs and Other Resource Use Increased drug treatment costs Other increase in costs: Other: uncertain unit cost compared to existing treatments Reduced drug treatment costs Other reduction in costs: None identified Other Issues Clinical uncertainty or other research question identified: expert opinion suggests that in terms of performance it would be important to establish efficacy of tildrakizumab vs the more commonly used biologics adalimumab and ustekizumab. None identified It is suggested that 10% of patients with psoriasis also have a psoriatic arthopathy, an important future research question, therefore, would be the efficacy in treating joint disease g. REFERENCES 1 ClinicalTrials.gov. A study to evaluate the efficacy and safety/tolerability of subcutaneous MK in participants with moderate-to-severe chronic plaque psoriasis (MK ). Accessed 17 March American Academy of Dermatology working group. Guidelines for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology 2008;58: Patient.co.uk. Psoriasis. November Accessed 17 March Psoriasis Association. About psoriasis March Accessed 17 March National Institute for Health and Clinical Excellence. The assessment and management of psoriasis. Clinical Guideline CG153. Manchester: NICE; October Armstrong AW, Schupp C, Wu J et al. Quality of life and work productivity impairment among psoriasis patients: findings from the national psoriasis foundation survey data PLOS ONE 2012;7(12):e NIHR Horizon Scanning Centre. Brodalumab for moderate to severe plaque psoriasis. University of Birmingham, May National Institute for Health and Care Excellence. Apremilast for treating moderate to severe plaque psoriasis. Final scope. London: NICE; October Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. National clinical guideline 121. Edinburgh: SIGN; October NIHR Horizon Scanning Centre. Apremilast for psoriasis. University of Birmingham, January g Expert personal communication. 9
10 11 National Institute for Health and Care Excellence. Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology. Commissioning guide: Implementing NICE guidance. London: NICE; November 2012 (update). 12 Health & Social Care Information Centre. Hospital episode statistics for England. Inpatient statistics, Office for National Statistics. Mortality statistics: deaths registered in England and Wales (Series DR) British Association of Dermatologists & Primary Care Dermatology Society. Recommendations for the initial management of psoriasis. October PCDS%20Psoriasis%20reviewed% pdf Accessed 12 October Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis British Journal of Dermatology 2009;161(5): NIHR Horizon Scanning Centre. Dimethyl fumarate for plaque psoriasis. University of Birmingham, November Hsu S, Papp KA, Lebwohl MG et al. Consensus guidelines for the management of plaque psoriasis. Archives of Dermatology 2012;148(1): Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis British Journal of Dermatology 2009;161(5): National Institute for Health and Care Excellence. Psoriasis: final scope. London: NICE; December ClinicalTrials.gov. A 52-week, phase 3, randomised, active comparator and placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous SCH /MK3222, followed by an optional long-term safety extension study, in subjects with moderate to severe chronic plaque psoriasis. Accessed 3 February ClinicalTrials.gov. A 65-week, phase 3, randomised, placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (SCH /MK- 3222), followed by an optional long-term safety extension study, in subjects with moderate-tosevere chronic plaque psoriasis (protocol No. MK ). Accessed 17 March Langley RGB, Thaci D, Papp KA et al. MK-3222, an anti-il-23p19 humanized monoclonal antibody, provides significant improvement in psoriasis over 52 weeks of treatment that is maintained after discontinuation of dosing. Journal of the American Academy of Dermatology 2014;5(70):supplement 1, AB ClinicalTrials.gov. Randomised, double-blinded, placebo-controlled, parallel-design, dose-range finding study of subcutaneous SCH in subjects with moderate-to-severe chronic plaque psoriasis (study P05495). Accessed 17 March The Royal Pharmaceutical Society. British National Formulary. BNF
Horizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationHorizon Scanning Centre May Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524
Horizon Scanning Centre May 2014 Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524 This briefing is based on information available at the time of research and a limited literature
More informationHorizon Scanning Centre January Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652
Horizon Scanning Centre January 2013 Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652 This briefing is based on information available at the time of research and a limited literature search. It is not
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Dimethyl fumarate for treating moderate to severe Draft scope (pre-referral) Draft remit/appraisal objective To appraise
More informationRisankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis
NIHR Innovation Observatory Evidence Briefing: November 2017 Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis NIHRIO (HSRIC) ID: 9708 NICE ID: 9191 LAY SUMMARY Plaque
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationKEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.
KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd.
ixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd. 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationUstekinumab for the treatment of moderate to severe psoriasis
DOI: 10.3310/hta13suppl3/10 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Ustekinumab for the treatment of moderate to severe psoriasis E Gospodarevskaya, J Picot, K Cooper, E Loveman* and A Takeda
More informationFinal Appraisal Report. Etanercept (Enbrel. Pfizer Limited. Advice No: 0210 March Recommendation of AWMSG
Final Appraisal Report Etanercept (Enbrel ) Pfizer Limited Advice No: 0210 March 2010 Recommendation of AWMSG Etanercept (Enbrel ) is not recommended for use within NHS Wales for the treatment of chronic
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationInfliximab (Remicade) for paediatric ulcerative colitis - second line
Infliximab (Remicade) for paediatric ulcerative colitis - second line September 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442
Ixekizumab for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 NICE 2017. All rights reserved. Subject to Notice of rights
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationUSTEKINUMAB. London New Drugs Group APC/DTC Briefing Document. May 2009
Page 1 London New Drugs Group APC/DTC Briefing Document USTEKINUMAB Contents Summary 1 Background 4 Clinical efficacy 5 Cost implications 9 Reference list 10 Appendices 11 Produced for the London New Drugs
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationHorizon Scanning Centre November Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
Horizon Scanning Centre November 2014 Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects SUMMARY NIHR HSC ID: 8515 This briefing is based on information
More informationustekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.
Original Issue Date (Created): January 1, 2010 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Preauthorization Requirements for Ustekinumab (STELARA ) Note:
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Single Technology Appraisal Apremilast for treating moderate to severe plaque psoriasis ID679 Consultee and commentator comment form Please use
More informationTechnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 NICE 2017. All rights
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationHorizon Scanning Centre March Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468
Horizon Scanning Centre March 2014 Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468 This briefing is based on information available at the time
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368
Apremilast for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368 NICE 2015. All rights reserved. Contents 1 Guidance...
More informationA systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C
A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C Authors' objectives To compare the effectiveness of currently available treatments
More informationBrodalumab for treating moderate to severe plaque psoriasis [ID878]
Brodalumab for treating moderate to severe plaque psoriasis [ID878] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationdimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 Almirall Limited
dimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 Almirall Limited 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION IXEKIZUMAB (Taltz Eli Lilly Canada Inc.) Indication: Moderate to Severe Plaque Psoriasis Recommendation: The CADTH Canadian Drug Expert Committee
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationapremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.
apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationIxekizumab for treating moderate to severe plaque psoriasis [ID904]
Thank you for agreeing to make a submission on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationSTELARA (ustekinumab)
STELARA (ustekinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More informationEtanercept: a new option in paediatric plaque psoriasis
: a new option in paediatric plaque psoriasis Steve Chaplin MSc, MRPharmS, Medical Writer, Dr David Atherton MA, MB, BChir, FRCP, Honorary Consultant in Paediatric Dermatology, Great Ormond Street Hospital
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationGuselkumab for treating moderate to severe plaque psoriasis [ID1075]
Guselkumab for treating moderate to severe plaque psoriasis [ID1075] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta199
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta199 NICE 2018. All rights reserved. Subject
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationrhngf for neurotrophic keratitis first line
September 2015 Horizon Scanning Research & Intelligence Centre rhngf for neurotrophic keratitis first line LAY SUMMARY This briefing is based on information available at the time of research and a limited
More informationEtanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103. Issue date: July 2006
Issue date: July 2006 Review date: deferred until 2010 Etanercept and efalizumab for the treatment of adults with psoriasis NICE technology appraisal guidance 103 NICE technology appraisal guidance 103
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationHorizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationResearch Protocol Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people 7 th June 2016
Research Protocol Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and 7 th June 2016 Produced by CRD/CHE Technology Assessment Group (Centre for Reviews and Dissemination/Centre
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #410: Psoriasis: Clinical Response to Systemic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes Meaningful Measure Area: Management of Chronic
More informationTargeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value
Targeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value Condition Update Final Background and Scope January 9, 2018 Background Psoriasis is a common
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationPsoriasis. Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement
Psoriasis Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement Copyright 2017 by Sea Courses Inc. All rights reserved. No part
More informationPSORIASIS BEST PRACTICE IN MANAGEMENT
PSORIASIS BEST PRACTICE IN MANAGEMENT Objectives Discuss pathology of psoriasis Review types of psoriasis Review triggers and factors affecting disease severity Common comorbidity review Review first and
More informationHorizon Scanning Centre July Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711
Horizon Scanning Centre July 2014 Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711 This briefing is based on information available at the time of research and a limited
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationSecukinumab (plaque psoriasis)
IQWiG Reports Commission No. A17-08 Secukinumab (plaque psoriasis) Benefit assessment according to 35a Social Code Book V 1 (new scientific findings) Extract 1 Translation of Sections 2.1 to 2.6 of the
More informationAR101 peanut allergy immunotherapy for adult and paediatric patients
AR101 peanut allergy immunotherapy for adult and paediatric patients NIHRIO (HSRIC) ID: 11815 NIHR Innovation Observatory Evidence Briefing: May 2017 NICE ID: 8773 LAY SUMMARY Food allergy occurs when
More informationCOSENTYX (secukinumab)
COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationAn otherwise healthy 12-year-old
1105 Photo Rounds.finalREV 10/19/05 2:05 PM Page 947 A young girl with scaly skin plaques The patient had numerous thick red plaques on her back and the extensor surfaces of elbows, knees, and forearms
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationTicagrelor (Brilique) for peripheral arterial disease
July 2016 Horizon Scanning Research & Intelligence Centre Ticagrelor (Brilique) for peripheral arterial disease LAY SUMMARY This briefing is based on information available at the time of research and a
More informationErtugliflozin for type 2 diabetes mellitus
October 2016 Horizon Scanning Research & Intelligence Centre Ertugliflozin for type 2 diabetes mellitus NIHR HSRIC ID: 7712; 11910; 12223; 12238 Lay summary Ertugliflozin is a new drug to treat type 2
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationHorizon Scanning Centre July Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line
Horizon Scanning Centre July 2014 Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line SUMMARY NIHR HSC ID: 2635 This briefing is based on information available
More informationCurrent treatment options in the management of psoriasis
Drug review Current treatment options in the management of psoriasis Eleanor Higgins MB BCh, BAO, MRCPI and Trevor Markham MD, BAO, MRCPI SPL is a common chronic condition and treatment choice primarily
More informationTechnology appraisal guidance Published: 26 July 2006 nice.org.uk/guidance/ta103
Etanercept and efalizumab for the treatment of adults with psoriasis Technology appraisal guidance Published: 26 July 2006 nice.org.uk/guidance/ta103 NICE 2018. All rights reserved. Subject to Notice of
More informationSecukinumab for treating moderate to severe plaque psoriasis. Erratum
Aberdeen HTA Group Secukinumab for treating moderate to severe plaque psoriasis Erratum Completed 2 March 2015 This report was commissioned by the NIHR HTA Programme as project number 13/129/01 Contains
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More information